Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

ABL

Abacus Global Management Moves Listing to NYSE

Abacus Global Management, Inc. (NYSE: ABX), a leader in the alternative asset management space, has announced its decision to transfer the listing of its Class A common stock to the New York Stock Exchange (NYSE) from the NASDAQ. The company expects to begin trading as a NYSE listed company on or about December 30, 2025, under the new ticker symbol "ABX."

Furthermore, the company's 9.875% fixed rate senior notes due 2028, currently trading on NASDAQ under symbol "ABLLL," will transfer to NYSE and are expected to begin trading on or about December 30, 2025, under the new ticker symbol "ABXL."

The move to transfer the listing to the NYSE is seen as a strategic decision to create long-term shareholder value, according to Jay Jackson, Chairman and CEO of Abacus. The NYSE's global reach, strong institutional investor base, and deep market liquidity are expected to provide an exceptional foundation for the company's continued growth.

In addition to the listing transfer, it's important to note that the company's Class A common stock will continue to trade under the ticker symbol "ABL" on NASDAQ until the close of market on December 29, 2025.

Abacus Global Management, known for its specialization in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services, is set to leverage the advantages and unique offerings of the NYSE platform as it executes its strategy to deliver value for its shareholders.

The press release did not include specific financial metrics or comparisons to the previous period. As a result of these announcements, the company's shares have moved -0.23% on the market, and are now trading at a price of $8.74. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS